90 results
8-K
KDNY
Chinook Therapeutics Inc
11 Aug 23
Termination of a Material Definitive Agreement
4:31pm
application for atrasentan for the treatment of Immunoglobulin A nephropathy, which approval does not impose a risk evaluation and mitigation strategy
DEFM14A
KDNY
Chinook Therapeutics Inc
10 Jul 23
Proxy related to merger
4:01pm
strategy (“REMs”) that is related to liver toxicity (“Milestone 1”); and
$2.00 if the FDA approves prior to December 21, 2029 (the “Milestone 2 Period … applicable laws. Such forward-looking statements include statements relating to our strategy, goals, future focus areas and the value of the proposed
PREM14A
KDNY
Chinook Therapeutics Inc
27 Jun 23
Preliminary proxy related to merger
4:02pm
in patients (“Indication 1”), which approval does not impose a risk evaluation and mitigation strategy (“REMs”) that is related to liver toxicity … . Such forward-looking statements include statements relating to our strategy, goals, future focus areas and the value of the proposed transaction
DEFA14A
KDNY
Chinook Therapeutics Inc
20 Jun 23
Additional proxy soliciting materials
9:05am
strategy to preserve kidney function broadly in CKD.
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical
8-K
EX-99.1
9myqrjuzxru9920c
20 Jun 23
CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 days
9:00am
DFAN14A
ujo2q
12 Jun 23
Additional proxy materials by non-management
9:41am
DEFA14A
3c4i1f 4kvsdk70x
12 Jun 23
Additional proxy soliciting materials
7:05am
8-K
EX-2.1
0bftpj2up 5jn
12 Jun 23
Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG
7:00am
8-K
nvlh8
12 Jun 23
Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG
7:00am
PRE 14A
fmeg2
17 Apr 23
Preliminary proxy
4:51pm
424B5
ijs1 zl8s
10 Nov 22
Prospectus supplement for primary offering
4:59pm
424B5
xyg2zi ck
25 May 22
Prospectus supplement for primary offering
4:15pm
424B5
ki6qz2t6
24 May 22
Prospectus supplement for primary offering
4:26pm
S-3ASR
qm4uxo8q8g0ya0ewoyys
24 May 22
Automatic shelf registration
4:01pm
8-K
EX-99.1
fzbgsiazym x7q
12 May 22
Chinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
4:07pm